E Fund Management Co. Ltd. Grows Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

E Fund Management Co. Ltd. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 37.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,551 shares of the company’s stock after purchasing an additional 4,476 shares during the period. E Fund Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $505,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its holdings in Intellia Therapeutics by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after purchasing an additional 18,987 shares during the period. Spire Wealth Management boosted its holdings in Intellia Therapeutics by 3,789.0% in the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock valued at $119,000 after purchasing an additional 3,789 shares during the period. Vestmark Advisory Solutions Inc. purchased a new position in Intellia Therapeutics in the fourth quarter valued at $8,110,000. Axxcess Wealth Management LLC boosted its holdings in Intellia Therapeutics by 4.0% in the fourth quarter. Axxcess Wealth Management LLC now owns 15,592 shares of the company’s stock valued at $475,000 after purchasing an additional 594 shares during the period. Finally, Los Angeles Capital Management LLC boosted its holdings in Intellia Therapeutics by 3.7% in the fourth quarter. Los Angeles Capital Management LLC now owns 11,695 shares of the company’s stock valued at $357,000 after purchasing an additional 422 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intellia Therapeutics

In related news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the transaction, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on NTLA shares. Canaccord Genuity Group lifted their price target on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. The Goldman Sachs Group downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Wolfe Research started coverage on Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

Intellia Therapeutics Stock Down 3.7 %

NTLA stock traded down $0.88 during trading on Wednesday, hitting $23.00. The company had a trading volume of 1,373,978 shares, compared to its average volume of 1,474,757. The firm has a market cap of $2.22 billion, a PE ratio of -4.25 and a beta of 1.85. Intellia Therapeutics, Inc. has a 1-year low of $19.37 and a 1-year high of $47.48. The firm has a 50-day moving average price of $25.64 and a 200-day moving average price of $27.22.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. The firm had revenue of ($1.92) million for the quarter, compared to analysts’ expectations of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same quarter in the previous year, the firm posted ($1.40) EPS. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.57 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.